← Companies|Grünenthal
Gr

Grünenthal

Aachen DEFounded 19464,500 employees
Private CappharmaPrivateCNS
Platform: Pain Specialty
Market Cap
N/A
All Drugs
4
Clinical Trials
8
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
DarasertibGR-600Phase 12Small MoleculeNectin-4PARPiMigraineMDD
GR-6650GR-6650NDA/BLA2Small MoleculePLK4SGLT2iParkinson'sCKD
GR-8075GR-8075Preclinical2Cell TherapyKRASG12CCD3xCD20RettHCC
SurabrutinibGR-9592Phase 22NanobodyRETHPK1iHCCDLBCL
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (8)
2026-01-21
Surabrutinib Ph2 Data
HCC
Past
2027-07-10
Surabrutinib Ph2 Data
DLBCL
Ph2 Data
2028-05-21
GR-6650 Ph3 Readout
Parkinson's
Ph3 Readout
2029-03-07
GR-8075 Interim
Rett
Interim
2029-10-02
Darasertib Interim
Migraine
Interim
2029-10-07
Darasertib Interim
MDD
Interim
2031-07-19
GR-8075 Interim
HCC
Interim
2031-09-13
GR-6650 Ph3 Readout
Parkinson's
Ph3 Readout